<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980248</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1850-HPP-101</org_study_id>
    <nct_id>NCT04980248</nct_id>
  </id_info>
  <brief_title>Study of ALXN1850 in Participants With Hypophosphatasia (HPP)</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic&#xD;
      (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and&#xD;
      subcutaneous (SC) to adults with HPP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Study participants will be enrolled into 3 cohorts in a sequential fashion.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Of Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single IV And Multiple SC Doses Of ALXN1850</measure>
    <time_frame>Predose through up to 168 hours following each dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) Of Single IV And Multiple SC Doses Of ALXN1850</measure>
    <time_frame>Predose through up to 168 hours following each dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration Versus Time Curve Within The Dosing Interval (AUCtau) Values Of The First SC Versus IV Administration</measure>
    <time_frame>Predose through up to 168 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Plasma Concentrations Of Inorganic Pyrophosphate (PPi)</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Plasma Concentrations Of Pyridoxal-5'-Phosphate (PLP)</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Plasma Concentrations Of PLP/Pyridoxal (PL) Ratio</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hypophosphatasia</condition>
  <arm_group>
    <arm_group_label>ALXN1850</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALXN1850</intervention_name>
    <description>ALXN1850 will be administered as an IV infusion and via the SC route.</description>
    <arm_group_label>ALXN1850</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed clinical diagnosis of HPP&#xD;
&#xD;
          -  Not anticipated to require further treatment with enzyme replacement therapy to treat&#xD;
             participant's HPP after study completion&#xD;
&#xD;
          -  Willing and able to follow protocol-specified contraception requirements&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary or secondary hyperparathyroidism or hypoparathyroidism&#xD;
&#xD;
          -  Fracture within 12 weeks of screening&#xD;
&#xD;
          -  Current or relevant history of unstable physical or psychiatric illness&#xD;
&#xD;
          -  Significant allergies&#xD;
&#xD;
          -  Asfotase alfa use within 6 months and/or positive for asfotase alfa antidrug&#xD;
             antibody/neutralizing antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPP</keyword>
  <keyword>enzyme replacement therapy</keyword>
  <keyword>low alkaline phosphatase</keyword>
  <keyword>tissue-nonspecific alkaline phosphatase</keyword>
  <keyword>TNSALP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

